Success in male infertility trials is measured as improvement in semen parameters (count, motility, morphology), increased testosterone, or recovery of spermatogenesis permitting natural or assisted conception. Approximately 30–50% of treated men showed measurable improvement in sperm parameters within 3–6 months; however, clinically meaningful improvement (achieving WHO normal thresholds or achieving paternity) occurred in 20–35%. Response is better in men with partial spermatogenesis impairment (oligozoospermia) than complete azoospermia. Prior chemotherapy exposure negatively impacts recovery; men with testicular trauma or infection may respond better. Approximately 40–50% reported no significant change in semen parameters post-treatment.
Male infertility trials are the smallest cohort among studied conditions, reflecting disease prevalence and therapeutic complexity. Three actively recruiting studies indicate emerging clinical interest. Published data predominantly come from small preclinical and early-phase clinical series. Some trials documented improvements in semen parameters (sperm concentration, motility, morphology) following MSC infusion into testicular tissue; a few azoospermic patients recovered some spermatogenesis permitting natural conception or assisted reproduction. Testosterone levels increased in responsive cohorts, suggesting Leydig-cell regeneration. However, study heterogeneity, small sample sizes, and limited controls restrict conclusions. Mechanism studies support germ-cell niche regeneration, but direct in-vivo confirmation in humans remains incomplete. Long-term paternity outcomes are inadequately documented.
Am I a candidate? → · Male Infertility: full overview → · Male Infertility cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估